• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

(20S)G-Rh2 通过靶向膜联蛋白 A2 抑制 NF-κB 调控的上皮间质转化。

(20S)G-Rh2 Inhibits NF-κB Regulated Epithelial-Mesenchymal Transition by Targeting Annexin A2.

机构信息

Key Laboratory for Molecular Enzymology and Engineering of the Ministry of Education, School of Life Sciences, Jilin University, Changchun 130012, China.

出版信息

Biomolecules. 2020 Mar 31;10(4):528. doi: 10.3390/biom10040528.

DOI:10.3390/biom10040528
PMID:32244350
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7225922/
Abstract

(1) Background: Epithelial-mesenchymal transition (EMT) is an essential step for cancer metastasis; targeting EMT is an important path for cancer treatment and drug development. NF-κB, an important transcription factor, has been shown to be responsible for cancer metastasis by enhancing the EMT process. Our previous studies showed that (20S)Ginsenoside Rh2 (G-Rh2) inhibits NF-κB activity by targeting Anxa2, but it is still not known whether this targeted inhibition of NF-κB can inhibit the EMT process. (2) Methods: In vivo (20S)G-Rh2-Anxa2 interaction was assessed by cellular thermal shift assay. Protein interaction was determined by immuno-precipitation analysis. NF-κB activity was determined by dual luciferase reporter assay. Gene expression was determined by RT-PCR and immuno-blot. EMT was evaluated by wound healing and Transwell assay and EMT regulating gene expression. (3) Results: Anxa2 interacted with the NF-κB p50 subunit, promoted NF-κB activation, then accelerated mesenchymal-like gene expression and enhanced cell motility; all these cellular processes were inhibited by (20S)G-Rh2. In contrast, these (20S)G-Rh2 effect were completely eliminated by overexpression of Anxa2-K301A, an (20S)G-Rh2-binding-deficient mutant of Anxa2. (4) Conclusion: (20S)G-Rh2 inhibited NF-κB activation and related EMT by targeting Anxa2 in MDA-MB-231 cells.

摘要

(1) 背景:上皮-间质转化(EMT)是癌症转移的重要步骤;靶向 EMT 是癌症治疗和药物开发的重要途径。NF-κB 是一种重要的转录因子,通过增强 EMT 过程被证明与癌症转移有关。我们之前的研究表明,(20S)人参皂苷 Rh2(G-Rh2)通过靶向 Anxa2 抑制 NF-κB 活性,但尚不清楚这种针对 NF-κB 的靶向抑制是否能抑制 EMT 过程。

(2) 方法:通过细胞热转移分析评估体内(20S)G-Rh2-Anxa2 相互作用。通过免疫沉淀分析确定蛋白相互作用。通过双荧光素酶报告基因检测法测定 NF-κB 活性。通过 RT-PCR 和免疫印迹测定基因表达。通过划痕愈合和 Transwell 测定以及 EMT 调节基因表达评估 EMT。

(3) 结果:Anxa2 与 NF-κB p50 亚基相互作用,促进 NF-κB 激活,然后加速间充质样基因表达并增强细胞迁移;所有这些细胞过程都被(20S)G-Rh2 抑制。相反,通过过表达 Anxa2-K301A(Anxa2 的一种与(20S)G-Rh2 结合缺陷的突变体),完全消除了(20S)G-Rh2 的这些作用。

(4) 结论:(20S)G-Rh2 通过在 MDA-MB-231 细胞中靶向 Anxa2 抑制 NF-κB 激活及其相关的 EMT。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/5602213b4e76/biomolecules-10-00528-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/df456e5dc14b/biomolecules-10-00528-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/dea0e9238b7f/biomolecules-10-00528-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/26da3b9f7808/biomolecules-10-00528-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/3da54811149f/biomolecules-10-00528-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/5602213b4e76/biomolecules-10-00528-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/df456e5dc14b/biomolecules-10-00528-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/dea0e9238b7f/biomolecules-10-00528-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/26da3b9f7808/biomolecules-10-00528-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/3da54811149f/biomolecules-10-00528-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/bb65/7225922/5602213b4e76/biomolecules-10-00528-g005.jpg

相似文献

1
(20S)G-Rh2 Inhibits NF-κB Regulated Epithelial-Mesenchymal Transition by Targeting Annexin A2.(20S)G-Rh2 通过靶向膜联蛋白 A2 抑制 NF-κB 调控的上皮间质转化。
Biomolecules. 2020 Mar 31;10(4):528. doi: 10.3390/biom10040528.
2
The identification of molecular target of (20S) ginsenoside Rh2 for its anti-cancer activity.(20S)人参皂苷Rh2抗癌活性分子靶点的鉴定。
Sci Rep. 2017 Sep 29;7(1):12408. doi: 10.1038/s41598-017-12572-4.
3
(20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2.(20S) 人参皂苷 Rh2 通过靶向膜联蛋白 A2 抑制 STAT3/VEGF 信号通路。
Int J Mol Sci. 2021 Aug 27;22(17):9289. doi: 10.3390/ijms22179289.
4
S100A11 functions as novel oncogene in glioblastoma via S100A11/ANXA2/NF-κB positive feedback loop.S100A11 通过 S100A11/ANXA2/NF-κB 正反馈环在胶质母细胞瘤中作为新的癌基因发挥作用。
J Cell Mol Med. 2019 Oct;23(10):6907-6918. doi: 10.1111/jcmm.14574. Epub 2019 Aug 20.
5
Aphthous ulcer drug inhibits prostate tumor metastasis by targeting IKKɛ/TBK1/NF-κB signaling.口疮性溃疡药物通过靶向 IKKɛ/TBK1/NF-κB 信号通路抑制前列腺肿瘤转移。
Theranostics. 2018 Sep 9;8(17):4633-4648. doi: 10.7150/thno.26687. eCollection 2018.
6
Identification of natural compounds targeting Annexin A2 with an anti-cancer effect.鉴定具有抗癌作用的靶向膜联蛋白 A2 的天然化合物。
Protein Cell. 2018 Jun;9(6):568-579. doi: 10.1007/s13238-018-0513-z. Epub 2018 Mar 5.
7
20(S)-ginsenoside Rh2 as agent for the treatment of LMN-CRC via regulating epithelial-mesenchymal transition.20(S)-人参皂苷 Rh2 通过调节上皮-间充质转化治疗 LMN-CRC 的应用。
Biosci Rep. 2020 Mar 27;40(3). doi: 10.1042/BSR20191507.
8
Ginsenoside Rg3 inhibits epithelial-mesenchymal transition (EMT) and invasion of lung cancer by down-regulating FUT4.人参皂苷Rg3通过下调FUT4抑制肺癌的上皮-间质转化(EMT)和侵袭。
Oncotarget. 2016 Jan 12;7(2):1619-32. doi: 10.18632/oncotarget.6451.
9
Ginsenoside Rh2 induces apoptosis and inhibits epithelial-mesenchymal transition in HEC1A and Ishikawa endometrial cancer cells.人参皂苷 Rh2 诱导 HEC1A 和 Ishikawa 子宫内膜癌细胞凋亡并抑制上皮-间充质转化。
Biomed Pharmacother. 2017 Dec;96:871-876. doi: 10.1016/j.biopha.2017.09.033. Epub 2017 Nov 6.
10
Metformin reverses mesenchymal phenotype of primary breast cancer cells through STAT3/NF-κB pathways.二甲双胍通过 STAT3/NF-κB 通路逆转原发性乳腺癌细胞的间充质表型。
BMC Cancer. 2019 Jul 23;19(1):728. doi: 10.1186/s12885-019-5945-1.

引用本文的文献

1
Quantitative Changes in the Proteome of Chronically Inflamed Lacrimal Glands From a Sjögren's Disease Animal Model.来自干燥综合征动物模型的慢性炎症泪腺蛋白质组的定量变化
Invest Ophthalmol Vis Sci. 2025 Apr 1;66(4):44. doi: 10.1167/iovs.66.4.44.
2
Ginsenosides: changing the basic hallmarks of cancer cells to achieve the purpose of treating breast cancer.人参皂苷:改变癌细胞的基本特征以达到治疗乳腺癌的目的。
Chin Med. 2023 Sep 25;18(1):125. doi: 10.1186/s13020-023-00822-9.
3
Structure Modification of Ginsenoside Rh and Cytostatic Activity on Cancer Cells.

本文引用的文献

1
Preparation of Polyethylene Glycol-Ginsenoside Rh1 and Rh2 Conjugates and Their Efficacy against Lung Cancer and Inflammation.聚乙二醇-人参皂苷 Rh1 和 Rh2 缀合物的制备及其对肺癌和炎症的疗效。
Molecules. 2019 Nov 29;24(23):4367. doi: 10.3390/molecules24234367.
2
Long noncoding RNAs and exosomal lncRNAs: classification, and mechanisms in breast cancer metastasis and drug resistance.长非编码 RNA 和外泌体 lncRNA:在乳腺癌转移和耐药中的分类和机制。
Oncogene. 2020 Jan;39(5):953-974. doi: 10.1038/s41388-019-1040-y. Epub 2019 Oct 10.
3
Mesencephalic Astrocyte-Derived Neurotrophic Factor Inhibits Liver Cancer Through Small Ubiquitin-Related Modifier (SUMO)ylation-Related Suppression of NF-κB/Snail Signaling Pathway and Epithelial-Mesenchymal Transition.
人参皂苷Rh的结构修饰及其对癌细胞的细胞抑制活性
ACS Omega. 2023 May 1;8(19):17245-17253. doi: 10.1021/acsomega.3c01665. eCollection 2023 May 16.
4
Ginsenosides from as Key Modulators of NF-κB Signaling Are Powerful Anti-Inflammatory and Anticancer Agents.三七总皂苷作为 NF-κB 信号通路的关键调节剂,是一种强大的抗炎和抗癌药物。
Int J Mol Sci. 2023 Mar 24;24(7):6119. doi: 10.3390/ijms24076119.
5
Overcoming therapeutic resistance to platinum-based drugs by targeting Epithelial-Mesenchymal transition.通过靶向上皮-间质转化克服对铂类药物的治疗耐药性。
Front Oncol. 2022 Oct 14;12:1008027. doi: 10.3389/fonc.2022.1008027. eCollection 2022.
6
(20S) Ginsenoside Rh2-Activated, Distinct Apoptosis Pathways in Highly and Poorly Differentiated Human Esophageal Cancer Cells.(20S)高、低分化人食管癌细胞中,人参皂苷 Rh2 激活的不同凋亡途径。
Molecules. 2022 Aug 31;27(17):5602. doi: 10.3390/molecules27175602.
7
(20S) Ginsenoside Rh2 Inhibits STAT3/VEGF Signaling by Targeting Annexin A2.(20S) 人参皂苷 Rh2 通过靶向膜联蛋白 A2 抑制 STAT3/VEGF 信号通路。
Int J Mol Sci. 2021 Aug 27;22(17):9289. doi: 10.3390/ijms22179289.
8
Clinical significance of CD34CD117/CD34CD117 myeloblast-associated gene expression in t(8;21) acute myeloid leukemia.t(8;21) 急性髓系白血病中 CD34CD117/CD34CD117 髓系原始细胞相关基因表达的临床意义。
Front Med. 2021 Aug;15(4):608-620. doi: 10.1007/s11684-021-0836-7. Epub 2021 Mar 23.
9
Advances in Ginsenosides.人参皂苷的研究进展
Biomolecules. 2020 Apr 28;10(5):681. doi: 10.3390/biom10050681.
中脑星形胶质细胞衍生神经营养因子通过小泛素相关修饰物(SUMO)化相关抑制 NF-κB/Snail 信号通路和上皮-间充质转化抑制肝癌。
Hepatology. 2020 Apr;71(4):1262-1278. doi: 10.1002/hep.30917. Epub 2020 Jan 26.
4
EMT and Cancer: More Than Meets the Eye.急诊医疗技术员和癌症:比表面所见更多。
Dev Cell. 2019 May 6;49(3):313-316. doi: 10.1016/j.devcel.2019.04.026.
5
Ginsenoside Rh2 Ameliorates Doxorubicin-Induced Senescence Bystander Effect in Breast Carcinoma Cell MDA-MB-231 and Normal Epithelial Cell MCF-10A.人参皂苷 Rh2 减轻阿霉素诱导的乳腺癌细胞 MDA-MB-231 和正常上皮细胞 MCF-10A 的衰老旁分泌效应。
Int J Mol Sci. 2019 Mar 12;20(5):1244. doi: 10.3390/ijms20051244.
6
Annexin A2 Silencing Inhibits Proliferation and Epithelial-to-mesenchymal Transition through p53-Dependent Pathway in NSCLCs.膜联蛋白A2沉默通过p53依赖途径抑制非小细胞肺癌的增殖和上皮-间质转化
J Cancer. 2019 Jan 29;10(5):1077-1085. doi: 10.7150/jca.29440. eCollection 2019.
7
Immunomodulatory Effects of (24R)-Pseudo-Ginsenoside HQ and (24S)-Pseudo-Ginsenoside HQ on Cyclophosphamide-Induced Immunosuppression and Their Anti-Tumor Effects Study.(24R)-伪原人参二醇和(24S)-伪原人参二醇对环磷酰胺诱导的免疫抑制的免疫调节作用及其抗肿瘤作用研究。
Int J Mol Sci. 2019 Feb 15;20(4):836. doi: 10.3390/ijms20040836.
8
A Hierarchical Regulatory Landscape during the Multiple Stages of EMT.EMT 多个阶段的层次调节景观。
Dev Cell. 2019 Feb 25;48(4):539-553.e6. doi: 10.1016/j.devcel.2018.12.023. Epub 2019 Jan 31.
9
EMT Transition States during Tumor Progression and Metastasis.肿瘤进展和转移过程中的 EMT 过渡态。
Trends Cell Biol. 2019 Mar;29(3):212-226. doi: 10.1016/j.tcb.2018.12.001. Epub 2018 Dec 26.
10
Ginsenoside Rh2 Inhibits Angiogenesis in Prostate Cancer by Targeting CNNM1.人参皂苷Rh2通过靶向CNNM1抑制前列腺癌血管生成。
J Nanosci Nanotechnol. 2019 Apr 1;19(4):1942-1950. doi: 10.1166/jnn.2019.16404.